A rat model for choroidal neovascularization using subretinal lipid hydroperoxide injection.
The purpose of this study was to develop and characterize a rat model of choroidal neovascularization (CNV) as occurs in age-related macular degeneration. The lipid hydroperoxide 13(S)-hydroperoxy-9Z,11E-octadecadienoic acid (HpODE) is found in submacular Bruch's membrane in aged humans and has been reported to generate neovascularization in a rabbit model. Three weeks after a single subretinal injection of 30 microg of HpODE, eyes of Sprague-Dawley rats were harvested. Follow-up fluorescein angiography was done on other animals until 5 weeks postinjection. Histological studies, immunohistochemical staining, and flatmount choroids for CNV measurements were performed. In addition, we used murine neuronal, bovine endothelial, and human ARPE19 cells for testing the in vitro effects of HpODE. CNV developed in 85.7% of HpODE-injected eyes. The neovascular areas were significantly greater in HpODE-injected eyes compared with those in control eyes (P = 0.023). The CNV had maximum dye leakage at 3 weeks, which subsided by the 5th week. Histologically, CNV extended from the choriocapillaris into the subretinal space. ED1-positive macrophages were recruited to the site. In vitro assays demonstrated that only 30 ng/ml HpODE induced cell proliferation and migration of endothelial cells. HpODE-induced CNV was highly reproducible, and its natural course seems to be ideal for evaluating therapeutic modalities. Because HpODE has been isolated from aged humans, the HpODE-induced rat model seems to be a relevant experimental model for CNV in age-related macular degeneration.
Baba
Takayuki
T
Wilmer Ophthalmological Institute, Johns Hopkins University, School of Medicine, Baltimore, Maryland 21287, USA.
Bhutto
Imran A
IA
Merges
Carol
C
Grebe
Rhonda
R
Emmert
David
D
McLeod
D Scott
DS
Armstrong
Donald
D
Lutty
Gerard A
GA
D000818:Animals; D002417:Cattle; D002460:Cell Line; D049109:Cell Proliferation; D002829:Choroid / Q000473:pathology / Q000648:ultrastructure; D020256:Choroidal Neovascularization / Q000139:chemically induced* / Q000473:pathology*; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D006801:Humans; D007267:Injections; D008054:Lipid Peroxides / Q000009:adverse effects*; D008268:Macular Degeneration / Q000473:pathology*; D008297:Male; D051379:Mice; D011817:Rabbits; D051381:Rats; D017207:Rats, Sprague-Dawley; D012160:Retina / Q000473:pathology / Q000648:ultrastructure
D008054:Lipid Peroxides
Exp Eye Res. 2002 Feb;74(2):301-8
11950240
Science. 2005 Apr 15;308(5720):419-21
15761120
Retina. 1999;19(2):141-7
10213241
Jpn J Ophthalmol. 1997 Sep-Oct;41(5):284-96
9363556
Invest Ophthalmol Vis Sci. 1994 Jul;35(8):3234-50
8045716
Invest Ophthalmol Vis Sci. 1987 Jul;28(7):1116-30
2439474
Immunology. 1985 Mar;54(3):589-99
3882559
Invest Ophthalmol Vis Sci. 1999 Aug;40(9):1891-8
10440240
Invest Ophthalmol Vis Sci. 2004 May;45(5):1544-52
15111613
Mol Vis. 2002 Apr 21;8:119-26
11979237
Exp Eye Res. 2003 Apr;76(4):463-71
12634111
Br J Ophthalmol. 1976 May;60(5):324-41
952802
Ophthalmology. 1993 Oct;100(10):1519-35
7692366
Invest Ophthalmol Vis Sci. 2009 Feb;50(2):870-7
18806290
Proc Natl Acad Sci U S A. 2005 May 17;102(20):7227-32
15870199
Science. 2005 Apr 15;308(5720):385-9
15761122
Exp Eye Res. 1982 Aug;35(2):157-71
7151884
Angiogenesis. 1998;2(1):93-104
14517379
Annu Rev Biochem. 1998;67:395-424
9759493
Exp Eye Res. 2005 Mar;80(3):369-78
15721619
Exp Eye Res. 2005 Aug;81(2):193-9
16080913
Invest Ophthalmol Vis Sci. 1993 Mar;34(3):477-87
7680639
Invest Ophthalmol Vis Sci. 2003 Aug;44(8):3578-85
12882810
Am J Pathol. 2006 Feb;168(2):639-48
16436677
J Leukoc Biol. 2003 Jul;74(1):25-32
12832439
J Neurochem. 2008 May;105(4):1187-97
18182060
Am J Pathol. 2003 Feb;162(2):413-25
12547700
Trans Am Ophthalmol Soc. 1996;94:411-30; discussion 430-1
8981707
Prog Retin Eye Res. 2009 Nov;28(6):393-422
19698799
Graefes Arch Clin Exp Ophthalmol. 1997 May;235(5):313-9
9176680
Trans Am Ophthalmol Soc. 1979;77:707-45
94717
Invest Ophthalmol Vis Sci. 1996 Jun;37(7):1236-49
8641827
Curr Eye Res. 2006 Apr;31(4):337-46
16603467
Science. 2005 Apr 15;308(5720):421-4
15761121
Exp Eye Res. 2006 Jan;82(1):99-110
16019000
Mol Vis. 2005 Jun 16;11:414-24
15988410
J Leukoc Biol. 1989 Dec;46(6):556-64
2572659
Free Radic Biol Med. 1991;11(1):81-128
1937131
Br J Ophthalmol. 2004 Sep;88(9):1217-22
15317719
Invest Ophthalmol Vis Sci. 2007 Apr;48(4):1801-7
17389514
Invest Ophthalmol. 1976 Jun;15(6):443-6
931687
Surv Ophthalmol. 2006 Mar-Apr;51(2):137-52
16500214
Invest Ophthalmol Vis Sci. 2006 Dec;47(12):5163-70
17122098
Surv Ophthalmol. 2003 May-Jun;48(3):257-93
12745003
Mol Vis. 2007 May 23;13:772-8
17563727